Targeting dendritic cells for priming cellular immune responses (original) (raw)

Abstract

The cardinal role of dendritic cells (DC) in priming adaptive immunity and in orchestrating immune responses against all classes of pathogens and also against tumors is well established. Their unique potential both to maintain self-tolerance and to initiate protective immune responses against foreign and/or dangerous structures is based on the functional diversity and flexibility of these cells. Tissue DC lining antigenic portals such as mucosal surfaces and the skin are specialized to take up a wide array of compounds including proteins, lipids, carbohydrates, glycoproteins, glycolipids and oligonucleotides, particles carrying such structures and apoptotic or necrotic cells. This process is facilitated by specialized receptors with high endocytic capacity, which provides potential targets for delivering designed molecules. The best route for targeting B-and/or T cell epitopes, however, is still the subject of intense investigation. Immature DC, which reside in various tissues, can be activated by pathogens, stress and inflammation or modified metabolic products, which induce mobilization of cells to draining lymph nodes where they act as highly potent professional antigen presenting cells. This is brought about by the ability to present their accumulated intracellular content for both CD4þ helper (Th) and CD8þ cytotoxic/cytolytic T lymphocytes (Tc/CTL). Engulfed proteins are processed intracellularly and their peptide fragments are transported to the cell surface in the context of major histocompatibility complex encoded class I and II molecules for presentation to Th cells and CTLs, respectively. The T cell priming capacity of DC, however, depends not only on antigen presentation but also on other features of DC.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (203)

  1. Abbas AK, Lichtman AH, Pober JS. 2000. Cellular and Molecular Immunology. W.B. Saunders: Philadelphia, PA; 29-30.
  2. Aderem A, Ulevitch RJ. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787.
  3. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. 1998a. Immature dendritic cells phagocy- tose apoptotic cells via alphavbeta5 and CD36, and cross- present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188: 1359-1368.
  4. Albert ML, Sauter B, Bhardwaj N. 1998b. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89.
  5. Albert ML, Kim JI, Birge RB. 2000. 5 integrin recruits the CrkII- Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat. Cell Biol. 2: 899-905.
  6. Almeida J, Bueno C, Alguero MC, Sanchez ML, de Santiago M, Escribano L, Diaz-Agustin B, Vaquero JM, Laso FJ, San Miguel JF, Orfao A. 2001. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage( À )/CD16( þ )/HLA-DR( þ )/CD14(-/lo) cells, CD14( þ ) monocytes, and CD16( À ) dendritic cells. Clin. Immunol. 100: 325-338.
  7. Andreesen R, Picht J, Lohr GW. 1983. Primary cultures of human blood-born macrophages grown on hydrophobic teflon membranes. J. Immunol. Meth. 56: 295-304.
  8. Ardavin C, Martinez del Hoyo G, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H. 2001. Origin and differentiation of dendritic cells. Trends Immunol. 22: 691- 700.
  9. Arndt SO, Vogt AB, Markovic-Plese S, Martin R, Moldenhauer G, Wolpl A, Sun Y, Schadendorf D, Hammerling GJ, Kropshofer H. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. Embo J. 19: 1241-1251.
  10. 312 P. GOGOLA ´K ET AL.
  11. Copyright # 2003 John Wiley & Sons, Ltd. J. Mol. Recognit. 2003; 16: 299-317
  12. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, de la Salle H, Schild H. 1999. Cutting edge: receptor- mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol. 162: 3757-3760.
  13. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JS. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4: 17-25.
  14. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK. 2000. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6: 435-442.
  15. Francois Bach J. 2003. Regulatory lymphocytes: regulatory T cells under scrutiny. Nat. Rev. Immunol. 3: 189-198.
  16. Banchereau J, Steinman RM. 1998. Dendritic cells and the con- trol of immunity. Nature 392: 245-252.
  17. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. A. Rev. Immunol. 18: 767-811.
  18. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to den- dritic cells and activate the NF-kappa B pathway. Int. Immu- nol. 12: 1539-1546.
  19. Bennett TA, Lynam EB, Sklar LA, Rogelj S. 1996. Hydroxamate- based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J. Immunol. 156: 3093-3097.
  20. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L. 2001. Horizontal transfer of onco- genes by uptake of apoptotic bodies. Proc. Natl Acad. Sci. USA 98: 6407-6411.
  21. Bergsmedh A, Szeles A, Spetz AL, Holmgren L. 2002. Loss of the p21(Cip1/Waf1) cyclin kinase inhibitor results in propagation of horizontally transferred DNA. Cancer Res. 62: 575-579.
  22. Bevan MJ. 1976. Cross-priming for a secondary cytotoxic re- sponse to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143: 1283-1288.
  23. Bhardwaj N, Young JW, Nisanian AJ, Baggers J, Steinman RM. 1993. Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses. J. Exp. Med. 178: 633-642.
  24. Binder RJ, Han DK, Srivastava PK. 2000. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1: 151-155.
  25. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. 1999. Genetic fusion of chemokines to a self tumor antigen induces pro- tective, T-cell dependent antitumor immunity. Nat. Biotech- nol. 17: 253-258.
  26. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733.
  27. Boon T, Old LJ. 1997. Cancer tumor antigens. Curr. Opin. Immunol. 9: 681-683.
  28. Bornstein P. 1992. Thrombospondins: structure and regulation of expression. Faseb J. 6: 3290-3299.
  29. Bouvier M, Wiley DC. 1998. Structural characterization of a soluble and partially folded class I major histocompatibility heavy chain/beta 2m heterodimer. Nat. Struct. Biol. 5: 377- 384.
  30. Brown BD, Lillicrap D. 2002. Dangerous liaisons: the role of 'danger' signals in the immune response to gene therapy. Blood 100: 1133-1140.
  31. Brugger W, Kreutz M, Andreesen R. 1991. Macrophage colony- stimulating factor is required for human monocyte survival and acts as a cofactor for their terminal differentiation to macrophages in vitro. J. Leukoc. Biol. 49: 483-488.
  32. Buschle M, Schmidt W, Zauner W, Mechtler K, Trska B, Kirlappos H, Birnstiel ML. 1997. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl Acad. Sci. USA 94: 3256-3261.
  33. Byrne A, Reen DJ. 2002. Lipopolysaccharide induces rapid pro- duction of IL-10 by monocytes in the presence of apoptotic neutrophils. J. Immunol. 168: 1968-1977.
  34. Chang CC, Wright A, Punnonen J. 2000. Monocyte-derived CD1aþ and CD1aÀ dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J. Immunol. 165: 3584-3591.
  35. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. 1999. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93: 780-786.
  36. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B. 2001. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isola- tion and flow cytometry. J. Immunol. Meth. 247: 163-174.
  37. Clayton A, Harris CL, Court J, Mason MD, Morgan BP. 2003. Antigen-presenting cell exosomes are protected from com- plement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunol. 33: 522-531.
  38. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl Acad. Sci. USA 95: 652-656.
  39. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446.
  40. Corinti S, Chiarantini L, Dominici S, Laguardia ME, Magnani M, Girolomoni G. 2002. Erythrocytes deliver Tat to interferon- gamma-treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro. J. Leukoc. Biol. 71: 652-658.
  41. Cui Z, Mumper RJ. 2002. Topical immunization using nanoengi- neered genetic vaccines. J. Control. Rel. 81: 173-184.
  42. Demeure CE, Tanaka H, Mateo V, Rubio M, Delespesse G, Sarfati M. 2000. CD47 engagement inhibits cytokine production and maturation of human dendritic cells. J. Immunol. 164: 2193- 2199.
  43. den Haan JM, Lehar SM, Bevan MJ. 2000. CD8( þ ) but not CD8( À ) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192: 1685-1696.
  44. Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ. 2000. Follicular dendritic cells carry MHC class II- expressing microvesicles at their surface. J. Immunol. 165: 1259-1265.
  45. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. 2002. Antitumor monoclonal antibodies enhance cross-pre- sentation ofcCellular antigens and the generation of mye- loma-specific killer T cells by dendritic cells. J. Exp. Med. 195: 125-133.
  46. Drakesmith H, O'Neil D, Schneider SC, Binks M, Medd P, Sercarz E, Beverley P, Chain B. 1998. In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen. Proc. Natl Acad. Sci. USA 95: 14903-14908.
  47. Drechsler Y, Chavan S, Catalano D, Mandrekar P, Szabo G. 2002. FcgammaR cross-linking mediates NF-kappaB activation, reduced antigen presentation capacity, and decreased IL-12 production in monocytes without modulation of myeloid dendritic cell development. J. Leukoc. Biol. 72: 657-667.
  48. Dziegielewska K, Brown WM, Deal A, Foster KA, Fry EJ, Saunders NR. 1996. The expression of fetuin in the develop- ment and maturation of the hemopoietic and immune sys- tems. Histochem. Cell Biol. 106: 319-330.
  49. Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, Lanzavecchia A, Fransen J, Figdor CG, Piguet V, van Kooyk Y. 2002. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presen- tation to T cells. J. Immunol. 168: 2118-2126.
  50. Fiebiger E, Meraner P, Weber E, Fang IF, Stingl G, Ploegh H, Maurer D. 2001. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen pre- sentation by dendritic cells. J. Exp. Med. 193: 881-892.
  51. Flores-Romo L. 2001. In vivo maturation and migration of den- dritic cells. Immunology 102: 255-262.
  52. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. 2001. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166: 4254-4259.
  53. Frisan T, Levitsky V, Polack A, Masucci MG. 1998. Phenotype- dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J. Immunol. 160: 3281-3289.
  54. Fritsche J, Moser M, Faust S, Peuker A, Buttner R, Andreesen R, Kreutz M. 2000. Molecular cloning and characterization of a human metalloprotease disintegrin-a novel marker for dendritic cell differentiation. Blood 96: 732-739.
  55. Fushimi T, Kojima A, Moore MA, Crystal RG. 2000. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105: 1383-1393.
  56. Gallucci S, Lolkema M, Matzinger P. 1999. Natural adjuvants: end- ogenous activators of dendritic cells. Nat. Med. 5: 1249-1255.
  57. Geier E, Pfeifer G, Wilm M, Lucchiari-Hartz M, Baumeister W, Eichmann K, Niedermann G. 1999. A giant protease with potential to substitute for some functions of the proteasome. Science 283: 978-981.
  58. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, Amigorena S, Hermine O, Durandy A. 1999. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 162: 4567-4575.
  59. Geissmann F, Launay P, Pasquier B, Lepelletier Y, Leborgne M, Lehuan A, Brousse N, Monteiro RC. 2001. A subset of human dendritic cells expresses IgA Fc receptors (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J. Immunol. 166: 346-352.
  60. Gluckman JC, Canque B, Rosenzwajg M. 2002. Dendritic cells: a complex simplicity. Transplantation 73: S3-S6.
  61. Gordon S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
  62. Grage-Griebenow E, Flad HD, Ernst M, Bzowska M, Skrzeczynska J, Pryjma J. 2000. Human MO subsets as defined by expres- sion of CD64 and CD16 differ in phagocytic activity and gen- eration of oxygen intermediates. Immunobiology 202: 42-50.
  63. Grage-Griebenow E, Zawatzky R, Kahlert H, Brade L, Flad H, Ernst M. 2001. Identification of a novel dendritic cell-like subset of CD64( þ )/CD16( þ ) blood monocytes. Eur. J. Im- munol. 31: 48-56.
  64. Granucci F, Andrews DM, Degli-Esposti MA, Ricciardi-Castagnoli P. 2002. IL-2 mediates adjuvant effect of dendritic cells. Trends Immunol. 23: 169-171.
  65. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, Colbert RA. 1998. Immunoproteasome assembly: coopera- tive incorporation of interferon gamma (IFN-gamma)-indu- cible subunits. J. Exp. Med. 187: 97-104.
  66. Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszi- nowski U, Kloetzel PM. 1995. The interferon-gamma-induci- ble 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J. Biol. Chem. 270: 23808-23815.
  67. Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C. 2001. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J. Exp. Med. 193: 1035-1044.
  68. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. 2002. Antigen presentation and T cell stimulation by den- dritic cells. A. Rev. Immunol. 20: 621-667.
  69. Guironnet G, Dezutter-Dambuyant C, Vincent C, Bechetoille N, Schmitt D, Peguet-Navarro J. 2002. Antagonistic effects of IL-4 and TGF-beta1 on Langerhans cell-related antigen expression by human monocytes. J. Leukoc. Biol. 71: 845-853.
  70. Haase C, Jorgensen TN, Michelsen BK. 2002. Both exogenous and endogenous interleukin-10 affects the maturation of bone-marrow-derived dendritic cells in vitro and strongly influences T-cell priming in vivo. Immunology 107: 489-499.
  71. Hackstein H, Morelli AE, Thomson AW. 2001. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol. 22: 437-442.
  72. Hammond SA, Walwender D, Alving CR, Glenn GM. 2001. Transcutaneous immunization: T cell responses and boost- ing of existing immunity. Vaccine 19: 2701-2707.
  73. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. 2002. Identification of a factor that links apoptotic cells to phagocytes. Nature 417: 182-187.
  74. Hashimoto SI, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K. 2000. Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression. Blood 96: 2206- 2214.
  75. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779.
  76. Heystek HC, Moulon C, Woltman AM, Garonne P, van Kooten C. 2002. Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation. J. Immunol. 168: 102-107.
  77. Hill HC, Conway TF Jr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. 2002. Cancer immunotherapy with inter- leukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62: 7254-7263.
  78. Hisamatsu H, Shimbara N, Saito Y, Kristensen P, Hendil KB, Fujiwara T, Takahashi E, Tanahashi N, Tamura T, Ichihara A, Tanaka K. 1996. Newly identified pair of proteasomal sub- units regulated reciprocally by interferon gamma. J. Exp. Med. 183: 1807-1816.
  79. Hoffmann PR, deCathelineau AM, Ogden CA, Leverrier Y, Brat- ton DL, Daleke DL, Ridley AJ, Fadok VA, Henson PM. 2001. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell Biol. 155: 649-659.
  80. Holmgren L, Szeles A, Rajnavolgyi E, Folkman J, Klein G, Ern- berg I, Falk KI. 1999. Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood 93: 3956-3963.
  81. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. 1996. In vivo cross- priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 4: 349-355.
  82. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. 2002. The mononuclear phagocyte system revisited. J. Leu- koc. Biol. 72: 621-627.
  83. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, Germain RN, Mellman I, Steinman RM. 2000. The formation of immunogenic major histocompatibility com- plex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191: 927-936.
  84. Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, Haines AM, Amir A, Husain R, Doshi R, Young LS, Mountain A. 2000. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat. Biotechnol. 18: 1273-1278.
  85. Jiang HR, Muckersie E, Robertson M, Xu H, Liversidge J, For- rester JV. 2002. Secretion of interleukin-10 or interleukin-12 by LPS-activated dendritic cells is critically dependent on time of stimulus relative to initiation of purified DC culture. J. Leukoc. Biol. 72: 978-985.
  86. Jonuleit H, Tuting T, Steitz J, Bruck J, Giesecke A, Steinbrink K, Knop J, Enk AH. 2000. Efficient transduction of mature CD83þ dendritic cells using recombinant adenovirus sup- pressed T cell stimulatory capacity. Gene Ther. 7: 249-254.
  87. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22: 394-400.
  88. Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL. 1999. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163: 699-707.
  89. Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, Telemo E. 2001. 'Tolerosomes' are produced by intestinal epithelial cells. Eur. J. Immunol. 31: 2892-2900.
  90. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. 1995. Metalloproteinase- mediated release of human Fas ligand. J. Exp. Med. 182: 1777-1783.
  91. Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. 1997. Interleukin-10 down-regulates MHC class II alphabeta pep- tide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7: 861-871.
  92. Kraft S, Novak N, Katoh N, Bieber T, Rupec RA. 2002. Aggrega- tion of the high-affinity IgE receptor Fc(epsilon)RI on human monocytes and dendritic cells induces NF-kappaB activa- tion. J. Invest. Dermatol. 118: 830-837.
  93. Kumamoto T, Huang EK, Paek HJ, Morita A, Matsue H, Valentini RF, Takashima A. 2002. Induction of tumor-specific protec- tive immunity by in situ Langerhans cell vaccine. Nat. Bio- technol. 20: 64-69.
  94. Kurts C, Cannarile M, Klebba I, Brocker T. 2001. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J. Immunol. 166: 1439-1442.
  95. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. 2002. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Meth. 270: 211-226.
  96. Larsson M, Berge J, Johansson AG, Forsum U. 1997. Human dendritic cells handling of binding, uptake and degradation of free and IgG-immune complexed dinitrophenylated hu- man serum albumin in vitro. Immunology 90: 138-146.
  97. Larsson M, Fonteneau JF, Bhardwaj N. 2001. Dendritic cells resurrect antigens from dead cells. Trends Immunol. 22: 141-148.
  98. Laupeze B, Amiot L, Bertho N, Grosset JM, Lehne G, Fauchet R, Fardel O. 2001. Differential expression of the efflux pumps P- glycoprotein and multidrug resistance-associated protein in human monocyte-derived dendritic cells. Hum. Immunol 62: 1073-1080.
  99. Laus R, Graddis TJ, Hakim I, Vidovic D. 2000. Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides. Nat. Biotechnol. 18: 1269-1272.
  100. Lechmann M, Berchtold S, Hauber J, Steinkasserer A. 2002. CD83 on dendritic cells: more than just a marker for matura- tion. Trends Immunol. 23: 273-275.
  101. Liu YJ. 2001. Dendritic cell subsets and lineages, and their func- tions in innate and adaptive immunity. Cell 106: 259-262.
  102. Loukissa A, Cardozo C, Altschuller-Felberg C, Nelson JE. 2000. Control of LMP7 expression in human endothelial cells by cytokines regulating cellular and humoral immunity. Cyto- kine 12: 1326-1330.
  103. Luhrs P, Schmidt W, Kutil R, Buschle M, Wagner SN, Stingl G, Schneeberger A. 2002. Induction of specific immune re- sponses by polycation-based vaccines. J. Immunol. 169: 5217-5226.
  104. Luster AD. 2002. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol. 14: 129-135.
  105. Lutz MB, Schuler G. 2002. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23: 445-449.
  106. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M. 1999. Dendritic cells up-regulate immunopro- teasomes and the proteasome regulator PA28 during ma- turation. Eur. J. Immunol. 29: 4037-4042.
  107. Magnani M, Chiarantini L, Mancini U. 1994. Preparation and characterization of biotinylated red blood cells. Biotechnol. Appl. Biochem. 20(Pt 3): 335-345.
  108. Maldonado-Lopez R, Moser M. 2001. Dendritic cell subsets and the regulation of Th1/Th2 responses. Sem. Immunol. 13: 275-282.
  109. Marriott I, Inscho EW, Bost KL. 1999. Extracellular uridine nu- cleotides initiate cytokine production by murine dendritic cells. Cell Immunol 195: 147-156.
  110. Martin P, Ruiz SR, del Hoyo GM, Anjuere F, Vargas HH, Lopez- Bravo M, Ardavin C. 2002. Dramatic increase in lymph node dendritic cell number during infection by the mouse mam- mary tumor virus occurs by a CD62L-dependent blood-borne DC recruitment. Blood 99: 1282-1288.
  111. Matko J, Bushkin Y, Wei T, Edidin M. 1994. Clustering of class I HLA molecules on the surfaces of activated and transformed human cells. J. Immunol. 152: 3353-3360.
  112. Maurer D, Fiebiger E, Reininger B, Ebner C, Petzelbauer P, Shi GP, Chapman HA, Stingl G. 1998. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presenta- tion. J. Immunol. 161: 2731-2739.
  113. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. 1998. Tumor immunogenicity is determined by the mechan- ism of cell death via induction of heat shock protein expres- sion. Nat Med 4: 581-587.
  114. Merad M, Sugie T, Engleman EG, Fong L. 2002. In vivo manip- ulation of dendritic cells to induce therapeutic immunity. Blood 99: 1676-1682.
  115. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges G, Palucka AK, Banchereau J. 2001. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 194: 1013-1020.
  116. Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendri- tic cells. Immunity 12: 107-117.
  117. Morelli AE, Zahorchak AF, Larregina AT, Colvin BL, Logar AJ, Takayama T, Falo LD, Thomson AW. 2001. Cytokine produc- tion by mouse myeloid dendritic cells in relation to differ- entiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98: 1512-1523.
  118. Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, Hobeika A, Mosca P, Clay T, Cumming RI, Fisher E, Clavien P, Proia AD, Niedzwiecki D, Caron D, Lyerly HK. 2000. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18: 3883-3893.
  119. Mosser DM. 2003. The many faces of macrophage activation. J. Leukoc. Biol. 73: 209-212.
  120. Mosser DM, Karp CL. 1999. Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Curr. Opin. Immunol. 11: 406-411.
  121. Mueller CG, Rissoan MC, Salinas B, Ait-Yahia S, Ravel O, Bridon JM, Briere F, Lebecque S, Liu YJ. 1997. Polymerase chain reaction selects a novel disintegrin proteinase from CD40- activated germinal center dendritic cells. J. Exp. Med. 186: 655-663.
  122. Mueller CG, Cremer I, Paulet PE, Niida S, Maeda N, Lebeque S, Fridman WH, Sautes-Fridman C. 2001. Mannose receptor ligand-positive cells express the metalloprotease decysin in the B cell follicle. J. Immunol. 167: 5052-5060.
  123. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. 1998. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16: 364-369.
  124. Nestle FO, Banchereau J, Hart D. 2001. Dendritic cells: on the move from bench to bedside. Nat. Med. 7: 761-765.
  125. Novak N, Bieber T, Katoh N. 2001. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J. Immunol. 167: 797-804.
  126. Ohashi K, Burkart V, Flohe S, Kolb H. 2000. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll- like receptor-4 complex. J. Immunol. 164: 558-561.
  127. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, Lund-Johansen F. 1997. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl Acad. Sci. USA 94: 12551-12556.
  128. Omata N, Yasutomi M, Yamada A, Iwasaki H, Mayumi M, Ohshima Y. 2002. Monocyte chemoattractant protein-1 se- lectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. J. Immunol. 169: 4861-4866.
  129. Osman M, Tortorella M, Londei M, Quaratino S. 2002. Expres- sion of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology 105: 73-82.
  130. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. 1998. Interferon-alpha and granulocyte-macro- phage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64: 358-367.
  131. Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA. 2002. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 16: 1484-1489.
  132. Platt N, da Silva RP, Gordon S. 1998. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell. Biol. 8: 365-372.
  133. Prevost JM, Pelley JL, Zhu W, D'Egidio GE, Beaudry PP, Pihl C, Neely GG, Claret E, Wijdenes J, Brown CB. 2002. Granulo- cyte-macrophage colony-stimulating factor (GM-CSF) and inflammatory stimuli up-regulate secretion of the soluble GM-CSF receptor in human monocytes: evidence for ecto- domain shedding of the cell surface GM-CSF receptor alpha subunit. J. Immunol. 169: 5679-5688.
  134. Probst P, Skeiky YA, Steeves M, Gervassi A, Grabstein KH, Reed SG. 1997. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen- presenting cells. Eur. J. Immunol. 27: 2634-2642.
  135. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, Maliszewski CR, Maraskovsky E. 1997. Devel- opmental pathways of dendritic cells in vivo: distinct func- tion, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 159: 2222-2231.
  136. Rafferty DE, Elfaki MG, Montgomery PC. 1996. Preparation and characterization of a biodegradable microparticle antigen/ cytokine delivery system. Vaccine 14: 532-538.
  137. Rajnavo ¨lgyi E, Lanyi A. 2003. Role of CD4þ T lymphocytes in antitumor immunity. Adv. Cancer Res. 87: 195-249.
  138. Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM, Muller WA. 1998. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl Acad. Sci. USA 95: 6924-6929.
  139. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. 1996. B lymphocytes secrete anti- gen-presenting vesicles. J. Exp. Med. 183: 1161-1172.
  140. Rappuoli R. 2001. Conjugates and reverse vaccinology to elim- inate bacterial meningitis. Vaccine 19: 2319-2322.
  141. Raychaudhuri S, Rock KL. 1998. Fully mobilizing host defense: building better vaccines. Nat Biotechnol 16: 1025-1031.
  142. Rea D, Johnson ME, Havenga MJ, Melief CJ, Offringa R. 2001. Strategies for improved antigen delivery into dendritic cells. Trends Mol. Med. 7: 91-94.
  143. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi- Castagnoli P, Amigorena S. 1999. Fcgamma receptor- mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presen- tation after immune complex internalization. J. Exp. Med. 189: 371-380.
  144. Reis e Sousa C. 2001. Dendritic cells as sensors of infection. Immunity 14: 495-498.
  145. Riedl E, Stockl J, Majdic O, Scheinecker C, Knapp W, Strobl H. 2000. Ligation of E-cadherin on in vitro-generated immature Langerhans-type dendritic cells inhibits their maturation. Blood 96: 4276-4284.
  146. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. 2000. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103: 757-768.
  147. Rock KL, Gamble S, Rothstein L. 1990. Presentation of exogen- ous antigen with class I major histocompatibility complex molecules. Science 249: 918-921.
  148. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M. 1999. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163: 130-136.
  149. Rosenberg SA. 1995. The Development of New Cancer Therapies Based on the Molecular Identification of Cancer Regression Antigens. Cancer J. Sci. Am. 1: 90.
  150. Rubartelli A, Poggi A, Zocchi MR. 1997. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extra- cellular calcium. Eur. J. Immunol. 27: 1893-1900.
  151. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. 2003. Vaccination with irradiated auto- logous tumor cells engineered to secrete granulocyte- macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21: 624-630.
  152. Sallusto F, Lanzavecchia A. 2000. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177: 134-140.
  153. Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas- Carvalho A, Sanchez-Schmitz G. 2001. CD16þ and CD16À human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4þ T cells. Int. Immunol. 13: 1571-1581.
  154. Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Stromin- ger JL, Stern LJ. 1999a. Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl Acad. Sci. USA 96: 15056-15061.
  155. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. 1999b. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc. Natl Acad. Sci. USA 96: 15050-15055.
  156. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendri- tic cells. J. Exp. Med. 191: 423-434.
  157. Savill J, Dransfield I, Gregory C, Haslett C. 2002. A blast from the past: clearance of apoptotic cells regulates immune re- sponses. Nat. Rev. Immunol. 2: 965-975.
  158. Scaffidi P, Misteli T, Bianchi ME. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.
  159. Schakel K, Poppe C, Mayer E, Federle C, Riethmuller G, Rieber EP. 1999. M-DC8þ leukocytes-a novel human dendritic cell population. Pathobiology 67: 287-290.
  160. Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U. 2003. Effects of gran- ulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell re- sponse to vaccination with tyrosinase peptides. Int. J. Can- cer 104: 188-194.
  161. Schmidt W, Buschle M, Zauner W, Kirlappos H, Mechtler K, Trska B, Birnstiel ML. 1997. Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl Acad. Sci. USA 94: 3262-3267.
  162. Schmidt-Wolf G, Schmidt-Wolf IG. 1995. Cytokines and clinical gene therapy. Eur. J. Immunol. 25: 1137-1140.
  163. Schnell S, Young JW, Houghton AN, Sadelain M. 2000. Retro- virally transduced mouse dendritic cells require CD4þ T cell help to elicit antitumor immunity: implications for the clin- ical use of dendritic cells. J. Immunol. 164: 1243-1250.
  164. Schnurr M, Then F, Galambos P, Scholz C, Siegmund B, Endres S, Eigler A. 2000. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J. Immunol. 165: 4704-4709.
  165. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-de- rived dendritic cells. J. Exp. Med. 195: 1279-1288.
  166. Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M. 2000. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up-or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164: 6147-6157.
  167. Shen Z, Reznikoff G, Dranoff G, Rock KL. 1997. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158: 2723-2730.
  168. Siedlar M, Frankenberger M, Ziegler-Heitbrock LH, Belge KU. 2000. The M-DC8-positive leukocytes are a subpopulation of the CD14þ CD16þ monocytes. Immunobiology 202: 11-17.
  169. Simon A, Dosztanyi Z, Rajnavolgyi E, Simon I. 2000. Function- related regulation of the stability of MHC proteins. Biophys. J. 79: 2305-2313.
  170. Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birken- meier G, Boudaly S, Mecheri S. 2003. Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J. Immunol. 170: 3037-3045.
  171. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal- Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ. 2002. Human epithelial cells trigger dendritic cell mediated allergic inflam- mation by producing TSLP. Nat. Immunol. 3: 673-680.
  172. Spetz AL, Patterson BK, Lore K, Andersson J, Holmgren L. 1999. Functional gene transfer of HIV DNA by an HIV receptor- independent mechanism. J. Immunol. 163: 736-742.
  173. Syrengelas AD, Chen TT, Levy R. 1996. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 2: 1038-1041.
  174. Tailleux L, Schwartz O, Herrmann JL, Pivert E, Jackson M, Amara A, Legres L, Dreher D, Nicod LP, Gluckman JC, Lagrange PH, Gicquel B, Neyrolles O. 2003. DC-SIGN is the major Myco- bacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 197: 121-127.
  175. Takahashi K, Honeyman MC, Harrison LC. 1997. Dendritic cells generated from human blood in granulocyte macrophage- colony stimulating factor and interleukin-7. Hum. Immunol. 55: 103-116.
  176. Tanaka K, Kasahara M. 1998. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon- gamma-inducible proteasome activator PA28. Immunol. Rev. 163: 161-176.
  177. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi- Castagnoli P, Raposo G, Amigorena S. 1999. Molecular characterization of dendritic cell-derived exosomes. Selec- tive accumulation of the heat shock protein hsc73. J. Cell Biol. 147: 599-610.
  178. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. 2001. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166: 7309-7318.
  179. Thery C, Zitvogel L, Amigorena S. 2002a. Exosomes: composi- tion, biogenesis and function. Nat. Rev. Immunol. 2: 569- 579.
  180. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. 2002b. Indirect activation of naive CD4þ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3: 1156-1162.
  181. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. 2001. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phago- cytosis activity of dendritic cells measure up with macro- phages? J. Control. Rel. 76: 59-71.
  182. Thiele L, Diederichs JE, Reszka R, Merkle HP, Walter E. 2003. Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials 24: 1409-1418.
  183. Tkaczyk C, Frandji P, Botros HG, Poncet P, Lapeyre J, Peronet R, David B, Mecheri S. 1996. Mouse bone marrow-derived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. J. Immunol. 157: 1720-1728.
  184. Torche AM, Le Corre P, Albina E, Jestin A, Le Verge R. 2000. PLGA microspheres phagocytosis by pig alveolar macro- phages: influence of poly(vinyl alcohol) concentration, nat- ure of loaded-protein and copolymer nature. J. Drug Target. 7: 343-354.
  185. Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, Mellman I. 2000. Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288: 522-527.
  186. Ulevitch RJ. 2000. Molecular mechanisms of innate immunity. Immunol. Res. 21: 49-54.
  187. Unkeless JC, Jin J. 1997. Inhibitory receptors, ITIM sequences and phosphatases. Curr. Opin. Immunol. 9: 338-343.
  188. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, Roberts DJ. 1999. Plasmodium falciparum-infected ery- throcytes modulate the maturation of dendritic cells. Nature 400: 73-77.
  189. Urban BC, Willcox N, Roberts DJ. 2001. A role for CD36 in the regulation of dendritic cell function. Proc. Natl Acad. Sci. USA 98: 8750-8755.
  190. Van den Eynde BJ, Morel S. 2001. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr. Opin. Immunol. 13: 147-153.
  191. van der Merwe PA. 2002. Formation and function of the immu- nological synapse. Curr. Opin. Immunol. 14: 293-298.
  192. Van Voorhis WC, Valinsky J, Hoffman E, Luban J, Hair LS, Steinman RM. 1983. Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J. Exp. Med. 158: 174-191.
  193. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. 2001. Human peripheral blood cells differentially recognize and res- pond to two distinct CPG motifs. J. Immunol. 166: 2372-2377.
  194. Viney JL. 2001. Immune fate decided by dendritic cell provoca- teurs. Trends Immunol. 22: 8-10.
  195. Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, Guyre PM, Ernstoff MS, Fanger MW. 2001. Exogenous antigen targeted to FcgammaRI on myeloid cells is pre- sented in association with MHC class I. J. Immunol. Meth. 248: 183-194.
  196. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. 2002. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23: 130-135.
  197. Watts C. 2001. Antigen processing in the endocytic compart- ment. Curr. Opin. Immunol. 13: 26-31.
  198. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigor- ena S, Zitvogel L. 2001. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross- priming. Nat. Med. 7: 297-303.
  199. Yang Y, Li Q, Ertl HC, Wilson JM. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung- directed gene therapy with recombinant adenoviruses. J. Virol. 69: 2004-2015.
  200. Yewdell JW, Norbury CC, Bennink JR. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8þ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73: 1-77.
  201. Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H, Cao X. 1999. Enhanced therapeutic efficacy of tumor RNA-pulsed dendri- tic cells after genetic modification with lymphotactin. Hum. Gene Ther. 10: 1151-1161.
  202. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. 1998. Eradica- tion of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4: 594-600.
  203. Zou GM, Tam YK. 2002. Cytokines in the generation and matura- tion of dendritic cells: recent advances. Eur. Cytokine Netw. 13: 186-199.